Sarepta Therapeutics (SRPT) is the lead sponsor of 9 active clinical trials listed on ClinicalTrials.gov[3], including 4 Phase 3[1], 2 Phase 1[2].
Trial NCT05881408[4] evaluates delandistrogene moxeparvovec in Duchenne Muscular Dystrophy with a target enrollment of 148 participants. Trial NCT06246513[5] evaluates SRP-9003 in Limb-girdle Muscular Dystrophy with a target enrollment of 17 participants. Trial NCT05967351[6] evaluates delandistrogene moxeparvovec in Duchenne Muscular Dystrophy with a target enrollment of 400 participants.
SRPT has 5 Form 4 insider filings recorded at the SEC in the past 30 days[7].